PureTech's Gelesis brings in $30M to back its FDA pitch on a new weight loss therapy with troublesome data
Gelesis has rounded up $30 million to take its mixed set of data on its weight loss therapy to regulators in the US and Europe.
The biotech, part of the PureTech group in Boston, did what it could last fall to whip up excitement for hitting one primary measure for efficacy — with 58% of the treatment arm losing at least 5% of their body weight during a study compared to 42% in the placebo group. But it also conceded that the study failed to demonstrate a 3% mean difference between the two, missing the co-primary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
